Third-party institutional trials our customers cite in their formulation dossiers, regulatory submissions and marketing claims.
Randomized cross-over trial evaluating 500mg Auronata BK-04 bark extract on postprandial glucose excursion after a standardized carbohydrate load.
Single-blind comparative study on barrier-impaired panels (SLS-stripped forearm) testing Auronata FL-12 hydrosol versus a marketed reference toner. Measured via corneometry and TEWL at 1, 4, 24h.
12-week double-blind RCT evaluating a 2% Auronata CF-S35 topical formulation versus placebo across mild-to-moderate seborrheic dermatitis of the scalp. Significant improvement on SCORAD across all severity strata.
In-vivo half-face split study evaluating 1% Auronata CF-OIL serum vs. placebo over 28 days with daily standardized UV exposure. Measured via MDA assay and TEWL.
Open-label, multi-center trial across four sites in India and Sri Lanka assessing oral Auronata CF-S20 standardized extract over 8 weeks in adults with chronic functional constipation.